Successful production of dengue vaccine after 20 years of research

This is considered the first step in preventing the mosquito-borne infection (dengue fever), which is life-threatening for millions of people worldwide every year.

Produced dengue vaccine in Mexico

Scientists have brought good news to many people around the world when they first announced the successful production of dengue vaccine in Mexico. This is considered the first step in preventing the mosquito-borne infection (dengue fever), which is life-threatening for millions of people worldwide every year.

In a telephone interview, Olivier Charmeil, the head of Sanofi (the company that successfully researched this vaccine), Dengvaxia (vaccine name) will soon be approved in Latin America and Asia in the next few weeks. The new drug is thought to prevent the development of four viruses that can cause dengue. Recently, dengue outbreaks are showing signs of outbreak in many countries such as Portugal, France, Florida and Japan and are at risk of spreading to many countries (WHO: World Health Organization).

Dengue fever is at increased risk in many countries around the world.

Statistics show that dengue is at increased risk in many countries around the world. Unlike malaria, an infectious disease is also transmitted by mosquitoes, dengue fever almost affects all populations in the regions of the world from wealthy urban areas to middle-income countries. Latin America, Asia or poor African countries. Typically, in Sao Paulo, due to a shortage of water, residents in this city often store water in old pots and tanks, which is an ideal environment for the growth and development of mosquitoes and agents. causing thousands of dengue cases this year. In Hawaii, there have been 139 confirmed cases of outbreaks of dengue in the past few years ago, most of which are local residents.

Dengvaxia is a vaccine that has been researched and developed over the past 20 years, amounting to EUR 1.5 billion, including production investments. Currently, Dengvaxia is waiting for approval in at least 19 different countries. In Mexico, the drug is expected to be used for people aged 9 to 45 in areas where dengue outbreaks occur.

According to calculations by Bloomberg experts, the amount of sales of this drug could reach 1.4 billion USD by 2020. Sanofi said: "Dengvaxia will be sold at an affordable price, fair, reasonable and lasting". "Some countries may be able to distribute this drug for free," said Guillaume Leroy, Sanofi's vice president of vaccine. Dengvaxia is also recommended not to be used for children under 9 years of age because it will be less effective. In a recent interview, Charmeil said: "We are making dengue preventable, we are proud of this."

People with dengue fever can lead to fatal complications.

People with dengue fever can lead to fatal complications. The disease has some noticeable manifestations such as bleeding gums, vomiting, rapid breathing and severe abdominal pain. Recent statistics confirm that there are up to 390 million people infected with dengue every year (WHO). In particular, more than 1% of these have not been treated promptly, effectively leading to death.

Along with the study of vaccines, many companies are also implementing many other research approaches to defeat viruses that cause dengue fever. In particular, Oxitec Ltd has come up with a solution to alter the gene of male mosquitoes that cause larvae or young mosquitoes to die early before they can spread the disease.